Last Price$143.1(8.0%)
Market Cap$18.5B
LTM Cash & Cash Equivalents
$892.8M
YoY Growth
+33.5%
3Y CAGR
+111.0%
5Y CAGR
+76.9%
Stock quality & Intrinsic value
6/10
50.4% overvalued
Natera, Inc. Cash & Cash Equivalents
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $5,747.0K | $30.5M | $87.2M | $28.9M | $15.3M | $12.6M | $46.4M | $61.9M | $48.7M | $84.4M | $466.0M | $642.1M |
Overvalued or undervalued?
Check the intrinsic value for NTRA
and see if it's the right time to invest.
Natera, Inc. (NTRA) Cash & Cash Equivalents comparison analysis
General
LTM Cash & Cash Equivalents
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Natera, Inc.NTRA
$892.8M
33.5%
111.0%
76.9%
Median Peer Set
$1,297.0M
(16.9%)
(3.3%)
1.5%
Thermo Fisher Scientific Inc.TMO
$4,009.0M
(50.4%)
(3.6%)
10.8%
Danaher CorporationDHR
$2,078.0M
(64.6%)
(7.0%)
(36.4%)
IQVIA Holdings Inc.IQV
$1,702.0M
23.7%
7.6%
15.3%
Laboratory Corporation of America HoldingsLH
$1,518.7M
182.9%
1.0%
35.1%
Agilent Technologies, Inc.A
$1,467.0M
(16.1%)
9.6%
3.7%
Illumina, Inc.ILMN
$1,127.0M
7.5%
(2.9%)
(11.2%)
Quest Diagnostics IncorporatedDGX
$549.0M
(20.0%)
(14.3%)
(14.4%)
Waters CorporationWAT
$325.4M
(17.6%)
(13.4%)
(0.6%)
IDEXX Laboratories, Inc.IDXX
$288.3M
(36.5%)
25.9%
26.1%
Mettler-Toledo International Inc.MTD
$59.4M
(15.0%)
(15.6%)
(22.2%)
NTRA key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 14.3 0.0% | 55.2 287.2% | 159.3 188.7% | 190.4 19.5% | 217.1 14.0% | 210.9 (2.8%) | 257.7 22.1% | 302.3 17.3% | 391.0 29.3% | 625.5 60.0% | 820.2 31.1% | 1,082.6 32.0% |
| Cost of Goods Sold (COGS) | 11.2 | 37.3 | 78.4 | 112.8 | 135.6 | 139.6 | 166.1 | 175.5 | 203.6 | 318.4 | 456.3 | 589.8 |
% margin | 3.1 21.7% | 17.9 32.4% | 80.9 50.8% | 77.5 40.7% | 81.5 37.5% | 71.3 33.8% | 91.6 35.6% | 126.9 42.0% | 187.4 47.9% | 307.1 49.1% | 364.0 44.4% | 492.7 45.5% |
| Operating Expenses | 22.3 | 43.2 | 80.2 | 137.3 | 178.0 | 205.4 | 206.2 | 257.5 | 403.7 | 775.2 | 905.0 | 939.0 |
| Research & Development Expenses (R&D) | 7.0 | 11.6 | 17.3 | 27.7 | 41.9 | 50.1 | 51.4 | 51.4 | 100.0 | 264.2 | 316.4 | 320.7 |
| Selling, General & Administrative Expenses (SG&A) | 15.3 | 31.6 | 62.9 | 109.6 | 136.1 | 155.3 | 154.9 | 206.2 | 303.6 | 511.0 | 588.6 | 618.3 |
% margin | (19.2) (134.8%) | (25.3) (45.8%) | 0.7 0.4% | (59.8) (31.4%) | (96.5) (44.4%) | (134.0) (63.5%) | (114.6) (44.5%) | (130.7) (43.2%) | (216.3) (55.3%) | (468.2) (74.8%) | (541.0) (66.0%) | (446.2) (41.2%) |
| Interest Income | 57.0 | 0.0 | 0.1 | 1.0 | 1.4 | 2.4 | 0.0 | 4.2 | 7.6 | 5.4 | 3.5 | 24.4 |
| Interest Expense | 0.0 | 11.9 | 4.2 | 3.5 | 0.5 | 4.2 | 10.5 | 10.7 | 15.1 | 8.3 | 9.3 | 12.6 |
| Pre-tax Income | (76.2) | (37.1) | (5.2) | (70.3) | (95.6) | (135.9) | (127.8) | (122.8) | (229.6) | (471.1) | (546.8) | (434.5) |
% effective tax rate | 0.0 0.0% | 12.0 (32.4%) | 2.5 (48.6%) | (9.9) 14.1% | 0.1 (0.1%) | 0.5 (0.3%) | 0.3 (0.3%) | 2.0 (1.6%) | 0.1 (0.0%) | 0.6 (0.1%) | 1.0 (0.2%) | 0.3 (0.1%) |
% margin | (76.2) (534.5%) | (37.1) (67.3%) | (5.2) (3.2%) | (70.3) (36.9%) | (95.8) (44.1%) | (136.3) (64.6%) | (128.2) (49.7%) | (124.8) (41.3%) | (229.7) (58.8%) | (471.7) (75.4%) | (547.8) (66.8%) | (434.8) (40.2%) |
| EPS | (24.37) | (1.01) | (0.14) | (2.68) | (1.86) | (2.56) | (2.22) | (1.79) | (2.84) | (5.21) | (5.57) | (3.78) |
| Diluted EPS | (24.37) | (1.01) | (0.14) | (2.68) | (1.86) | (2.54) | (2.22) | (1.79) | (2.84) | (5.21) | (5.57) | (3.78) |
% margin | (18.5) (129.8%) | (22.7) (41.2%) | 4.2 2.6% | (61.2) (32.2%) | (93.4) (43.0%) | (125.8) (59.6%) | (107.1) (41.6%) | (104.4) (34.5%) | (206.0) (52.7%) | (451.5) (72.2%) | (520.8) (63.5%) | (383.3) (35.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Natera, Inc.'s Cash & Cash Equivalents?
As of today, Natera, Inc.'s last 12-month Cash & Cash Equivalents is $892.8M, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Natera, Inc.'s Cash & Cash Equivalents growth rate?
Over the last year, Natera, Inc.'s Cash & Cash Equivalents growth was 33.5%. The average annual Cash & Cash Equivalents growth rates for Natera, Inc. have been 139.3% over the past three years, 76.9% over the past five years.
3) Is Natera, Inc.'s Cash & Cash Equivalents growth rate Good?
Over the last year, Natera, Inc.'s Cash & Cash Equivalents growth was 33.5%, which is higher than industry growth of (0.1%). It indicates that Natera, Inc.'s Cash & Cash Equivalents growth is Good.